

Supplemental online content for:

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With *EML4-ALK* Fusion Variant 5 Refractory to ALK Inhibitors

Jay Gong, MS; Jeffrey P. Gregg, MD; Weijie Ma, MD; Ken Yoneda, MD; Elizabeth H. Moore, MD; Megan E. Daly, MD; Yanhong Zhang, MD, MS; Melissa J. Williams, MD; and Tianhong Li, MD, PhD

J Natl Compr Canc Netw 2019;17(4):297–301

eTable 1: Summary of Patient's Clinical Course

eTable 2: Comparison of Tumor Genomic Profiling

eTable 1. Summary of Patient's Clinical Course

	Disease Site	Diagnosis	RT 1	Crizotinib	RT 2	Ceritinib	Alectinib	RT 3	Ceritinib	Pembrolizumab
Date		1/9/13	1/10/13-2/3/13	2/7/13-3/24/14 (13 mo)	5/31/13-6/13/13	4/4/14-2/15 (10 mo)	2/11/15-9/15 (7 mo)	1/21/16-2/3/16; 8/8/16-8/24/16; 9/7/16-9/20/16	2/11/16-10/20/16	C1: 11/7/16, C2: 12/8/16
Primary tumor	T2 = 2.3 × 1.5 cm	Left upper lobe		PD		PD	PD		PD	Symptomatic progression
N1	N1	Left hilum						30 Gy in 10 fractions to left hilum (8/8/16-8/24/16)		
N3	Right supraclavicular	x	?			PD	PD		PD	NA
M1b	Liver, spleen			PD		PD	PD		PD	NA
	Bones			PD		PD	PD		PD	
M1b, CNS disease	Brain	x	WBRT (1/10/13-2/3/13)	PD		PD	PD	WBRT, 25 Gy in 10 fractions (9/7/16-9/20/16)	PD	Symptomatic progression
	Spinal cord	x		PD	30 Gy in 10 fractions to T11-L1	PD	PD	30 Gy in 10 fractions to T4-T9 (1/21/16-2/3/16)	SD	PD
AEs				Grade 3 nausea, elevated transaminases		Grade 1 fatigue, dizziness, pedal edema			Pneumonia, GIB, G-tube, failure to thrive, DVT/PE, paralysis	Failure to thrive, bed-bound, shortness of breath, weakness

Abbreviations: AEs, adverse events; CNS, central nervous system; DVT, deep vein thrombosis; GIB, gastrointestinal bleeding; M, metastatic; N, nodal; NA, not available; PD, disease progression; PE, pulmonary embolism; RT, radiation therapy; SD, stable disease; WBRT, whole-brain radiation therapy.

eTable 2. Comparison of Tumor Genomic Profiling		
Assay	FoundationACT	FoundationOne
Specimen type	Blood	Tumor
Collection date	7/18/16; 11/7/16	7/12/16
Turnaround time (days from test order to report)	11 d	22 d
Genomic alterations	<i>EML4-ALK</i> fusion (variant 5)	<i>EML4-ALK</i> fusion (variant 5) <i>CDKN2B</i> loss <i>CDKN2A</i> loss <i>PTEN</i> loss exon 1 <i>FAS</i> loss <i>FBXW7</i> E113D MAF = 1.0%
Tumor mutational burden	NA	Intermediate; 15.17 Muts/Mb
Microsatellite status	NA	Microsatellite stable

Abbreviations: MAF, mutant allele frequency; Mb, megabase; Muts, mutations; NA, not available.